Table 2.
Patients’ characteristics considered in our study.
| Patients’ Characteristics | |
|---|---|
| Gender, n (%) | |
| Male | 46 (57%) |
| Female | 35 (57%) |
| Age, mean (SD) | 57 (12%) |
| Former smokers, n (%) | 34 (42%) |
| Onset symptoms n, (%) | |
| Pulmonary | 74 (91%) |
| Skin | 23 (28%) |
| Joint and muscles | 20 (25%) |
| Cardiac | 16 (20%) |
| Former smokers, n (%) | 34 (42%) |
| Organ involvement n, (%) | |
| Lymph node involvement | 59 (73%) |
| Lung | 71 (88%) |
| Renal/Hypercalciuria | 24 (29%) |
| Cutaneous | 23 (28%) |
| Osteoarticular | 20 (25%) |
| Abdominal | 10 (12%) |
| Cardiac | 16 (20%) |
| Neurological | 6 (7%) |
| Ocular | 16 (20%) |
| Lofgren’s syndrome | 11 (14%) |
| Scadding score n, (%) | |
| Stage 0 | 2 (2.5%) |
| Stage I | 8 (9.9%) |
| Stage II | 39 (48%) |
| Stage III | 15 (19%) |
| Stage IV | 17 (21%) |
| FEV1 n, (%) | |
| 70–100% | 68 (84%) |
| 50–69% | 11 (14%) |
| <50% | 2 (2.5%) |
| GCs* therapy n, (%) | 79 (98%) |
| Non GCs* therapy n, (%) | 58 (72%) |
| High ACE levels n, (%) | 26 (32%) |
| Wasfi score, median (IQR) | 7.78 (6.79, 9.27) |
| Hamzeh score, median (IQR) | 2 (1, 3) |
GCs*: Glucocorticoids.